by Leslie Citrome, MD, MPH; Andrew J. Cutler, MD; and Rakesh Jain, MD, MPH
Dopamine receptor–blocking agents (DRBAs) are thought to lead to the development of tardive dyskinesia (TD) through mechanisms that involve postsyn......READ MORE
by Leslie Citrome, MD, MPH; Andrew J. Cutler, MD; and Rakesh Jain, MD, MPH
Contemporary guidelines on the management of tardive dyskinesia (TD) include updated screening recommendations and reflect the US Food and Drug Adm......READ MORE
A leading theory of the pathogenesis of tardive dyskinesia (TD) involves an imbalance in the dopamine system involved in the coordination of moveme......READ MORE
Given the differing risk profiles of the available dopamine receptor–blocking agents (DRBAs) for tardive dyskinesia (TD), DRBA switching strategies......READ MORE
The emergence of vesicular monoamine transporter 2 (VMAT2) inhibitors has ushered in a new era in the management of tardive dyskinesia (TD). In cli......READ MORE
by Leslie Citrome, MD, MPH; Andrew J. Cutler, MD; and Rakesh Jain, MD, MPH
The introduction of the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine has marked a sea change in the manage......READ MORE
